Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer

Balraj Singh; Parminder Kaur; Sachin Gupta; Nirmal Guragai; Michael Maroules

doi:10.1177/23247096211035603

Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer

Balraj Singh, Parminder Kaur, Sachin Gupta, Nirmal Guragai, Michael Maroules

Department of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.

Original language	English (US)
Journal	Journal of Investigative Medicine High Impact Case Reports
Volume	9
DOIs	https://doi.org/10.1177/23247096211035603
State	Published - 2021

All Science Journal Classification (ASJC) codes

Epidemiology
Safety, Risk, Reliability and Quality
Safety Research

Access to Document

10.1177/23247096211035603

Cite this

@article{4e59696f83b6451f8af346823a2d2d28,

title = "Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer",

abstract = "Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.",

author = "Balraj Singh and Parminder Kaur and Sachin Gupta and Nirmal Guragai and Michael Maroules",

note = "Publisher Copyright: {\textcopyright} 2021 American Federation for Medical Research.",

year = "2021",

doi = "10.1177/23247096211035603",

language = "English (US)",

volume = "9",

journal = "Journal of Investigative Medicine High Impact Case Reports",

issn = "2324-7096",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Complete Response With Immunotherapy

T2 - A Case of Metastatic Bladder Cancer

AU - Singh, Balraj

AU - Kaur, Parminder

AU - Gupta, Sachin

AU - Guragai, Nirmal

AU - Maroules, Michael

PY - 2021

Y1 - 2021

N2 - Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.

AB - Bladder cancer is the most common urinary tract malignancy. Platinum-based chemotherapy is the first line of treatment in locally advanced or metastatic bladder cancer. Immunotherapy has become a novel therapy option in a broad variety of malignancies including bladder cancer. Immunotherapy is approved as first line of treatment in patients who are ineligible for platinum-based chemotherapy and second-line treatment for metastatic urothelial cancer who progressed after platinum-based treatments. We present the case of an 83-year-old female with metastatic bladder cancer who was chemotherapy ineligible and had complete response with immune checkpoint inhibitor pembrolizumab.

UR - http://www.scopus.com/inward/record.url?scp=85111441764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111441764&partnerID=8YFLogxK

U2 - 10.1177/23247096211035603

DO - 10.1177/23247096211035603

M3 - Article

C2 - 34308703

AN - SCOPUS:85111441764

SN - 2324-7096

VL - 9

JO - Journal of Investigative Medicine High Impact Case Reports

JF - Journal of Investigative Medicine High Impact Case Reports

ER -

Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this